DOLUTEGRAVIR SODIUM; LAMIVUDINE | N211994 | VIIV HEALTHCARE CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2024-08-02 | Terminated 2024-12-11 | — | |
ViiV Healthcare Company et al v. Cipla Limited et al 1 patentANDA 213579dolutegravir sodium; lamivudine | D. Del. | 2019-11-04 | Terminated 2022-04-04 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$105.26
per ea
Lowest NADAC/Unit
$105.26
per ea
Brand NDCs
2
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 49702024613DOVATO 50-300 MG TABLET | $105.26 | EA | Brand | — | 2026-06-17 |
| 49702024633DOVATO 50-300 MG TABLET | $105.26 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.